June 12, 2013—The Health Resources and Services Administration (HRSA) says Amgen’s decision to sell its biologic drug Neulasta at 340B pricing exclusively through specialty distributors “will not violate the 340B statute,” the agency has told both the association representing 340B hospitals and the 340B prime vendor.
Neulasta is an expensive, man-made human protein used to reduce the risk of infection in patients undergoing chemotherapy.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)